Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Barr Claravis 30 Mg Dose Will Compete With Ranbaxy’s Isotretinoin Generic

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche markets Accutane in 10 mg, 20 mg and 40 mg doses only.

You may also be interested in...

Cipher Receives “Approvable” Letter For CIP-Isotretinoin

FDA letter appears to resolve questions about the appropriate pathway for the acne medication.

Accutane iPLEDGE Debut On Track Despite Calls For Delay

FDA confirmed that it would not delay the March 1 implementation of the isotretinoin risk management program.

Biogen ‘Ready To Launch’ Aducanumab If It Gets The Chance

The company has identified 600 sites of care to treat Alzheimer's patients with aducanumab in the US and is confident on its pricing strategy, management said.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts